Stockscreener 앱 받기
0.7459
5.58%
-0.0441
시장 영업 전:
.71
-0.0359
-4.81%
Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스
Can Pasithea Therapeutics Corp grow without external funding2026 Momentum Check & Verified Short-Term Plans - baoquankhu1.vn
Should you buy the dip on Pasithea Therapeutics Corp2026 Weekly Recap & Stepwise Swing Trade Plans - baoquankhu1.vn
Loss Report: What is the next catalyst for Pasithea Therapeutics Corp Equity WarrantPortfolio Gains Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Wrap: Can Pasithea Therapeutics Corp grow without external funding2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Opaleye/James Silverman hold 2.49M shares of Pasithea (KTTA) in Schedule 13G - Stock Titan
Aug Opening: Whats the beta of Pasithea Therapeutics Corp stockTreasury Yields & Daily Chart Pattern Signals - baoquankhu1.vn
Buyback Watch: How does Pasithea Therapeutics Corp correlate with Nasdaq2026 Outlook & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Pasithea Therapeutics Corp reports results for the quarter ended December 31Earnings Summary - TradingView
KTTA Should I Buy - Intellectia AI
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity - Sahm
Trade Report: Is Pasithea Therapeutics Corp stock influenced by commodity prices2026 Biggest Moves & Technical Entry and Exit Tips - baoquankhu1.vn
Pasithea receives FDA fast track status for NF1 drug candidate By Investing.com - Investing.com Australia
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity - Investing News Network
Pasithea receives FDA fast track status for NF1 drug candidate - Investing.com
Pasithea Therapeutics Announces Grant of Fast Track - GlobeNewswire
KTTA SEC FilingsPasithea Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Signal Recap: Whats the beta of Pasithea Therapeutics Corp stockDividend Hike & Verified Entry Point Detection - baoquankhu1.vn
Pasithea Therapeutics Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Pasithea (NASDAQ: KTTA) highlights PAS-004 trials and NF1 focus - Stock Titan
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Reviewing Pasithea Therapeutics (NASDAQ:KTTA) and Forte Biosciences (NASDAQ:FBRX) - Defense World
Can Pasithea Therapeutics Corp disrupt its industryMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn
Highs Report: What is the long term forecast for Pasithea Therapeutics Corp stockQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Vericel (NASDAQ:VCEL) versus Pasithea Therapeutics (NASDAQ:KTTA) Critical Review - Defense World
Can Pasithea Therapeutics Corp sustain earnings growth2026 Chart Watch & High Yield Stock Recommendations - baoquankhu1.vn
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock - simplywall.st
Winners Losers: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly priced2026 Market Sentiment & Community Consensus Stock Picks - baoquankhu1.vn
Panic Selling: Whats the beta of Pasithea Therapeutics Corp Equity Warrant stockGDP Growth & Weekly High Momentum Picks - baoquankhu1.vn
Pasithea Therapeutics Corp expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Layoff Watch: What is the next catalyst for Pasithea Therapeutics Corp Equity WarrantQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Gains Report: Is Pasithea Therapeutics Corp Equity Warrant attractive for institutional investors2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Analyst Calls: How does Pasithea Therapeutics Corp correlate with Nasdaq2026 Momentum & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Aug EndMonth: What is Pasithea Therapeutics Corp Equity Warrants revenue forecast2026 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
Pasithea Therapeutics (KTTA) Expected to Announce Quarterly Earnings on Monday - Defense World
Smart Money: Whats the beta of Pasithea Therapeutics Corp stock2026 Historical Comparison & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Pullback Watch: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly priced2026 Price Action Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Fund Flows: Is Pasithea Therapeutics Corp Equity Warrant impacted by rising rates2026 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Will Pasithea Therapeutics Corp. Equity Warrant stock recover faster than market2026 Patterns & Entry Point Strategy Guides - Naître et grandir
RSI Check: What is Pasithea Therapeutics Corp Equity Warrants revenue forecastJuly 2025 Rallies & Expert Approved Momentum Ideas - baoquankhu1.vn
Earnings Recap: Whats the beta of Pasithea Therapeutics Corp stockMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Fed Watch: Whats the beta of Pasithea Therapeutics Corp Equity Warrant stockIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn
Certain Options of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026. - marketscreener.com
Certain Common Stock of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026. - marketscreener.com
KTTA PE Ratio & Valuation, Is KTTA Overvalued - Intellectia AI
KTTA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Coastlands entities hold 2.39M shares in Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
KTTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
What’s next for Pasithea Therapeutics Corp. stockTrade Entry Report & AI Enhanced Execution Alerts - mfd.ru
Pasithea Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CVI and Heights disclose 3.8% Pasithea (KTTA) stake via warrant holdings - Stock Titan
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Investing News Network
2.69%
0.25%
자본화:
|
볼륨(24시간):